22 results
Approved WMORecruiting
Currently, there are no curative treatment options for patients with Waldenstrom*s macroglobulinemia (WM) and there is no consensus on standard first line or relapse treatment. The proteasome inhibitor bortezomib has shown efficacy in WM, but is…
Approved WMORecruiting
To document clinical efficacy of ArthroSave*s Knee-Reviver at 1, 2 and 5 years after distraction by:1st: an increase in WOMAC score (pre-treatment vs. follow-up).2nd: an increase in radiographic joint space width (pre-treatment vs. follow-up)